Linde M van Veenendaal1, Alexander C J van Akkooi2, Cees Verhoef3, Dirk Jan Grünhagen3, W Martin C Klop4, Gerlof D Valk5, Margot E T Tesselaar1. 1. Departement of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 2. Departement of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 3. Departement of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 4. Departement of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 5. Departement of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Abstract
BACKGROUND: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine carcinoma of the skin. AIM: To describe clinical outcome and prognostic factors of MCC patients in two expert-centers. METHOD: Patients with histologically confirmed MCC in 1990-2014 were included. Data on patient, tumor characteristics and treatment were retrospectively collected. RESULTS: A total of 351 Patients were evaluated, 153 (44%) males, median age 74 years (range 28-94). Median follow-up time was 28 months (IQR 13-58). Median primary tumor size was 17 mm (range 2-135). At time of diagnosis 112 (32%) patients had lymph node metastases. The cohorts' 5-year overall survival (OS) was 58%. Using a competing risk analysis the 5-year relapse and MCC related death was 42% and 22%. Adjuvant radiation therapy (XRT) was associated with reduced recurrence (SDH 0.54; CI 0.3-0.9). Nodal involvement (SDH 2.7; CI 1.1-6.6) and the male gender were associated with higher MCC related death (SDH 3.1; CI 1.2-7.9) CONCLUSION: In a large cohort a low MCC related death, in the presence of a low OS was seen. This indicates that a significant number of MCC patients die due to other causes than MCC. Adjuvant XRT was associated with relapse. Male gender and nodal metastasis were associated with MCC related death.
BACKGROUND:Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine carcinoma of the skin. AIM: To describe clinical outcome and prognostic factors of MCC patients in two expert-centers. METHOD:Patients with histologically confirmed MCC in 1990-2014 were included. Data on patient, tumor characteristics and treatment were retrospectively collected. RESULTS: A total of 351 Patients were evaluated, 153 (44%) males, median age 74 years (range 28-94). Median follow-up time was 28 months (IQR 13-58). Median primary tumor size was 17 mm (range 2-135). At time of diagnosis 112 (32%) patients had lymph node metastases. The cohorts' 5-year overall survival (OS) was 58%. Using a competing risk analysis the 5-year relapse and MCC related death was 42% and 22%. Adjuvant radiation therapy (XRT) was associated with reduced recurrence (SDH 0.54; CI 0.3-0.9). Nodal involvement (SDH 2.7; CI 1.1-6.6) and the male gender were associated with higher MCC related death (SDH 3.1; CI 1.2-7.9) CONCLUSION: In a large cohort a low MCC related death, in the presence of a low OS was seen. This indicates that a significant number of MCC patients die due to other causes than MCC. Adjuvant XRT was associated with relapse. Male gender and nodal metastasis were associated with MCC related death.
Authors: Linde M van Veenendaal; Eduardo Bertolli; Catharina M Korse; W Martin C Klop; Margot E T Tesselaar; Alexander C J van Akkooi Journal: Ann Surg Oncol Date: 2020-06-11 Impact factor: 5.344
Authors: Aaron J Arroyave; James M Lewis; Miles Landry; James M McLoughlin; Laura M Enomoto Journal: Ann Surg Oncol Date: 2021-12-01 Impact factor: 5.344
Authors: Marita Yaghi; Paul Benedetto; John Greskovich; Roger Haber; Barbara Dominguez; Hong Liang; Zeina Nahleh; Rafael Arteta-Bulos Journal: JAAD Int Date: 2022-06-17
Authors: Sonja Levy; Maureen J B Aarts; Ferry A L M Eskens; Kristien B M I Keymeulen; Lukas B Been; Dirk Grünhagen; Alexander van Akkooi; Mathilde Jalving; Margot E T Tesselaar Journal: J Immunother Cancer Date: 2020-09 Impact factor: 13.751
Authors: Ellen M Zwijnenburg; Satish F K Lubeek; Johanna E M Werner; Avital L Amir; Willem L J Weijs; Robert P Takes; Sjoert A H Pegge; Carla M L van Herpen; Gosse J Adema; Johannes H A M Kaanders Journal: Cancers (Basel) Date: 2021-03-31 Impact factor: 6.639
Authors: Monika Dudzisz-Sledz; Paweł Sobczuk; Katarzyna Kozak; Tomasz Switaj; Hanna Kosela-Paterczyk; Anna Malgorzata Czarnecka; Slawomir Falkowski; Paweł Rogala; Tadeusz Morysinski; Mateusz Jacek Spalek; Marcin Zdzienicki; Tomasz Goryn; Marcin Zietek; Bozena Cybulska-Stopa; Stanisław Klek; Grazyna Kaminska-Winciorek; Barbara Ziolkowska; Anna Szumera-Cieckiewicz; Piotr Rutkowski Journal: Cancers (Basel) Date: 2022-01-14 Impact factor: 6.639